PainCeptor Pharma Corporation, a Canadian-based private biopharmaceutical company founded in 2004, specializes in developing safe and effective pharmaceuticals for managing chronic and acute pain. Their unique approach focuses on highly-selective organic molecules designed to intercept pain signals directly at the source.
Operating in the Health and Wellness and Pharmaceutical industries, PainCeptor has established a strong reputation for leveraging cutting-edge research and industrial collaborations to address unmet needs in pain management for debilitating diseases.
As of March 7, 2007, PainCeptor received a $24.40M Series B investment from a consortium of investors, including Lothian Partners, Desjardins Venture Capital, the Business Development Bank of Canada, and CDP Capital Technology Ventures. This funding bolstered PainCeptor's capability to advance its innovative pipeline and expand its market foothold.